Trial record 1 of 2 for:
bimagrumab | Obesity
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05616013 |
|
Recruitment Status :
Recruiting
First Posted : November 14, 2022
Last Update Posted : March 13, 2023
|
Sponsor:
Versanis Bio, Inc.
Information provided by (Responsible Party):
Versanis Bio, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Obesity Obese Overweight or Obesity | Biological: Bimagrumab Drug: Semaglutide Other: Bimagrumab Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 450 participants |
| Allocation: | Randomized |
| Intervention Model: | Factorial Assignment |
| Intervention Model Description: | The study is designed as a factorial of 3 semaglutide doses (none, 1.0 mg and 2.4 mg) and 3 bimagrumab doses (0, 10 and 30 mg/kg). |
| Masking: | Double (Participant, Investigator) |
| Masking Description: | In regards to bimagrumab and placebo-bimagrumab, the participants, Investigator and Sponsor will be blinded. Due to semaglutide being pre-filled, packaged and labeled by manufacturer, it is not possible to blind semaglutide. |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women |
| Actual Study Start Date : | November 16, 2022 |
| Estimated Primary Completion Date : | September 2024 |
| Estimated Study Completion Date : | September 2024 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Semaglutide
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Bimagrumab placebo
Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40
|
Other: Bimagrumab Placebo
Placebo |
|
Bimagrumab placebo + 1.0 mg semaglutide
Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule
|
Drug: Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Other Names:
Other: Bimagrumab Placebo Placebo |
|
Bimagrumab placebo + 2.4 mg semaglutide
Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40, and 2.4 mg s.c. semaglutide weekly per the dose escalation schedule
|
Drug: Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Other Names:
Other: Bimagrumab Placebo Placebo |
|
Experimental: 10 mg/kg bimagrumab
Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40
|
Biological: Bimagrumab
Human monoclonal antibody to the activin receptor type II |
|
10 mg/kg bimagrumab + 1.0 mg semaglutide
Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule
|
Biological: Bimagrumab
Human monoclonal antibody to the activin receptor type II Drug: Semaglutide Glucagon-like peptide-1 (GLP-1) receptor agonist
Other Names:
|
|
10 mg/kg bimagrumab + 2.4 mg semaglutide
Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16. 28 and 40, and 2.4 mg s.c. semaglutide weekly per the dose escalation schedule
|
Biological: Bimagrumab
Human monoclonal antibody to the activin receptor type II Drug: Semaglutide Glucagon-like peptide-1 (GLP-1) receptor agonist
Other Names:
|
|
Experimental: 30 mg/kg bimagrumab
Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40
|
Biological: Bimagrumab
Human monoclonal antibody to the activin receptor type II |
|
30 mg/kg bimagrumab + 1.0 mg semaglutide
Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16. 28, and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule
|
Biological: Bimagrumab
Human monoclonal antibody to the activin receptor type II Drug: Semaglutide Glucagon-like peptide-1 (GLP-1) receptor agonist
Other Names:
|
|
30 mg/kg bimagrumab + 2.4 mg semaglutide
Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40, and 2.4 mg s.c. semaglutide per the dose escalation schedule
|
Biological: Bimagrumab
Human monoclonal antibody to the activin receptor type II Drug: Semaglutide Glucagon-like peptide-1 (GLP-1) receptor agonist
Other Names:
|
Primary Outcome Measures :
- Change from baseline in body weight at 48 weeks [ Time Frame: At baseline and 48 weeks ]Percent change in total body weight will be measured from baseline to 48 weeks
Secondary Outcome Measures :
- Absolute change from baseline in WC (cm) at 48 weeks [ Time Frame: At baseline and 48 weeks ]Waist circumference will be measured in standing position with a non-stretchable measuring tape and to the nearest 0.1 centimeter (cm).
- Absolute change from baseline at 48 weeks in body fat mass in kilograms (kg) [ Time Frame: At baseline and 48 weeks ]Body weight will be measured in kilograms (kg) to the nearest 0.1 kg.
- Percent change from baseline at 48 weeks in body fat mass in kilograms (kg) [ Time Frame: At baseline and 48 weeks ]Body weight will be measured in kilograms (kg) to the nearest 0.1 kg and reported as a percentage.
- Absolute change from baseline at 48 weeks in visceral adipose tissue (VAT) or trunk fat mass by dual-energy x-ray absorptiometry (DXA) [ Time Frame: At baseline and 48 weeks ]Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
- Percent change from baseline at 48 weeks in visceral adipose tissue (VAT) or trunk fat mass by dual-energy x-ray absorptiometry (DXA) [ Time Frame: At baseline and 48 weeks ]Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
- Proportion of participants at 48 weeks with change in waist circumference ≥ 5 cm [ Time Frame: At baseline and 48 weeks ]Waist circumference will be measured in standing position with a non-stretchable measuring tape and to the nearest 0.1 centimeter (cm).
- Proportion of participants at 48 weeks with change in Body weight ≥ 10% [ Time Frame: At baseline and 48 weeks ]Body weight will be measured in kilograms (kg) to the nearest 0.1 kg.
- Proportion of participants at 48 weeks with change in Fat mass ≥ 5% ≥ 10% ≥ 15% [ Time Frame: At baseline and 48 weeks ]Dual energy X-ray absorptiometry (DXA) will be used to assess the change in fat mass.
- Proportion of participants at 48 weeks with change in Fat mass ≥ 10% with <5% decrease (or increase) in lean mass [ Time Frame: At baseline and 48 weeks ]Dual energy X-ray absorptiometry (DXA) will be used to assess body composition.
- Percentage of weight loss due to fat mass or lean mass at 48 weeks by dual-energy x-ray absorptiometry (DXA) [ Time Frame: At baseline and 48 weeks ]Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
- Absolute change from baseline at 48 weeks in fat mass (kg) by bioelectrical impedance analysis (BIA) [ Time Frame: At baseline and 48 weeks ]Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition. An estimate of total body water (TBW) is derived by measuring electrical impedance of body tissues, from which fat-free mass (FFM) and body fat (adiposity) are estimated.
- Percent change from baseline at 48 weeks in fat mass (kg) by bioelectrical impedance analysis (BIA) [ Time Frame: At baseline and 48 weeks ]Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition. An estimate of total body water (TBW) is derived by measuring electrical impedance of body tissues, from which fat-free mass (FFM) and body fat (adiposity) are estimated.
- Absolute change from baseline at 48 weeks in lean mass (kg) by bioelectrical impedance analysis (BIA) [ Time Frame: At baseline 48 weeks ]Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition and will be used to assess lean mass (kg)
- Absolute change from baseline at 48 weeks in lean mass (kg) by dual-energy x-ray absorptiometry (DXA) [ Time Frame: At baseline 48 weeks ]Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
- Percent change from baseline 48 weeks in lean mass (percent lean mass) by bioelectrical impedance analysis (BIA) [ Time Frame: At baseline and 48 weeks ]Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition and will be used to assess percent change in lean mass.
- Percent change from baseline 48 weeks in lean mass (percent lean mass) by dual energy X-ray absorptiometry (DXA) [ Time Frame: At baseline and 48 weeks ]Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
- Safety and tolerability measurements throughout 48 weeks by TEAEs [ Time Frame: Baseline and 48 weeks ]Incidence and severity of treatment emergent adverse events (TEAEs)
- Proportion of patients with change from baseline in BMI categories at 48 weeks [ Time Frame: At baseline and 48 weeks ]
BMI categories:
i. Healthy weight: 18.5 kg/m2 to 24.9 kg/m2 ii. Overweight: 25 kg/m2 to 29.9 kg/m2 iii. Obesity class 1: 30 kg/m2 to 34.9 kg/m2 iv. Obesity class II: 35 kg/m2 to 34.9 kg/m2 v. Obesity class III: ≥ 40 kg/m2
- Proportion of patients with change from baseline in WHtR ratio categories at 48 weeks [ Time Frame: At baseline and 48 weeks ]WHtR ratio categories: <0.5; 0.5-0.59; ≥0.6
- To assess treatment effects on glucose metabolism in HbA1c [ Time Frame: At baseline and 48 weeks ]Change from baseline in HbA1c (mmol/mol) at 48 weeks.
- To assess treatment effects on self-reported health status quality of life [ Time Frame: At baseline and 48 weeks ]Change from baseline at 48 weeks in Quality of Life Short Form 36 (SF-36) survey. To assess a subject's overall health related quality of life, as well as the physical functioning score. SF- 36 scores range from 0 (worst) to 100 (best)
- To assess treatment effects on self-reported weight-related quality of life [ Time Frame: At baseline and 48 weeks ]The Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite CT) is a 20-item modified survey instrument that is used to quantitatively assess an individual's perception of how their weight affects their day- to-day life, as well as the physical functioning score. Scores range from 0 (worst) to 100 (best)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- A written informed consent must be obtained before any study-related assessments are performed.
-
Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria:
- Two negative pregnancy tests (at screening and at randomization, prior to dosing)
- Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of bimagrumab/placebo i.v., and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of bimagrumab/placebo i.v.
- Body mass index (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)
- Stable body weight (± 5 kg) within 90 days of screening, and body weight <150 kg
- Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight
- Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration
Key Exclusion Criteria:
- History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to semaglutide (Ozempic® or Wegovy®)
- Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations
- Treatment with any medication for the indication of obesity within the past 30 days before screening
- Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥ 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion.
- Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection.
- Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (> 250 mL) within 14 days prior to the first dose
- Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the subject's safety or compliance with the protocol
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05616013
Contacts
| Contact: Kiran Dole, PharmD | 6173154410 | kiran.dole@versanisbio.com |
Locations
| United States, Alabama | |
| Versanis Investigational Site | Recruiting |
| Anniston, Alabama, United States, 36207 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Cullman, Alabama, United States, 35055 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| United States, Florida | |
| Versanis Investigational Site | Recruiting |
| Hialeah, Florida, United States, 33012 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Jacksonville, Florida, United States, 32256 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Lake Worth, Florida, United States, 33461 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| United States, Louisiana | |
| Versanis Investigational Site | Recruiting |
| Baton Rouge, Louisiana, United States, 70808 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| United States, New York | |
| Versanis Investigational Site | Not yet recruiting |
| New York, New York, United States, 10021 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanis.com | |
| United States, North Carolina | |
| Versanis Investigational Site | Recruiting |
| Monroe, North Carolina, United States, 28112 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| United States, South Carolina | |
| Versanis Investigational Site | Recruiting |
| Columbia, South Carolina, United States, 29322 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| United States, Texas | |
| Versanis Investigational Site | Recruiting |
| Sugar Land, Texas, United States, 77479 | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Australia | |
| Versanis Investigational Site | Not yet recruiting |
| Camberwell, Australia | |
| Contact: Kiran Dole, PharmsD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Not yet recruiting |
| Heidelberg Heights, Australia | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Morayfield, Australia | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Saint Leonards, Australia | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Sippy Downs, Australia | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| South Brisbane, Australia | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versansibio.com | |
| Versanis Investigational Site | Not yet recruiting |
| Southport, Australia | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| New Zealand | |
| Versanis Investigational Site | Active, not recruiting |
| Auckland, New Zealand | |
| Versanis Investigational Site | Recruiting |
| Auckland, New Zealand | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Christchurch, New Zealand | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Hamilton, New Zealand | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Nelson, New Zealand | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
| Versanis Investigational Site | Recruiting |
| Wellington, New Zealand | |
| Contact: Kiran Dole, PharmD Kiran.Dole@versanisbio.com | |
Sponsors and Collaborators
Versanis Bio, Inc.
Investigators
| Study Chair: | Kenneth Attie, MD | Versanis Biotechnology |
| Responsible Party: | Versanis Bio, Inc. |
| ClinicalTrials.gov Identifier: | NCT05616013 |
| Other Study ID Numbers: |
VER201-PH2-031 |
| First Posted: | November 14, 2022 Key Record Dates |
| Last Update Posted: | March 13, 2023 |
| Last Verified: | March 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Versanis Bio, Inc.:
|
bimagrumab semaglutide |
Additional relevant MeSH terms:
|
Obesity Overweight Overnutrition Nutrition Disorders Body Weight |
Antibodies, Monoclonal Antibodies, Blocking Immunologic Factors Physiological Effects of Drugs |